EU Industry Groups Urge Caution on Biosimilar Switching
By Zachary Brennan -
Published 09 March 2017
Three EU biopharmaceutical industry groups are offering key considerations to physicians when switching from a biologic reference product to its biosimilar or from one biosimilar of a reference product to another, according to a new position paper released on Thursday.
Categories: Europe, EC, EMA, Biologics and biotechnology, Compliance, Regulatory intelligence, Regulatory strategy
Tags: biosimilars, biosimilar switching, regulatory requirements biosimilars